Clinical trial
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With…
NCT00130494 · Spanish Breast Cancer Research Group, Other · Terminated
Key facts
| NCT number | NCT00130494 |
|---|---|
| Title | Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions |
| Official title | Multicenter, Open-label, Randomized Phase III Trial for Administration of Zoledronate to Breast Cancer Metastatic Patients With Non-symptomatic Bone Lesions |
| Lead sponsor | Spanish Breast Cancer Research Group, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Zoledronic acid |
| Enrollment | 97 |
| Start date | Aug 29, 2002 |
| Primary completion | Nov 20, 2006 |
| Completion | Oct 22, 2007 |
| First posted | Aug 15, 2005 |
| Last update posted | Apr 16, 2019 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: